187 related articles for article (PubMed ID: 27643881)
21. Expression of DNA repair proteins in endometrial cancer predicts disease outcome.
Mhawech-Fauceglia P; Wang D; Kim G; Sharifian M; Chen X; Liu Q; Lin YG; Liu S; Pejovic T
Gynecol Oncol; 2014 Mar; 132(3):593-8. PubMed ID: 24508840
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
[TBL] [Abstract][Full Text] [Related]
23. Dual-target inhibitors of PARP1 in cancer therapy: A drug discovery perspective.
Zhang J; Zhang J; Li H; Chen L; Yao D
Drug Discov Today; 2023 Jul; 28(7):103607. PubMed ID: 37146962
[TBL] [Abstract][Full Text] [Related]
24. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
25. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
26. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
Ding X; Ray Chaudhuri A; Callen E; Pang Y; Biswas K; Klarmann KD; Martin BK; Burkett S; Cleveland L; Stauffer S; Sullivan T; Dewan A; Marks H; Tubbs AT; Wong N; Buehler E; Akagi K; Martin SE; Keller JR; Nussenzweig A; Sharan SK
Nat Commun; 2016 Aug; 7():12425. PubMed ID: 27498558
[TBL] [Abstract][Full Text] [Related]
27. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Gan A; Green AR; Nolan CC; Martin S; Deen S
Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.
Wang GH; Zhao CM; Huang Y; Wang W; Zhang S; Wang X
Hum Pathol; 2018 Jan; 71():135-144. PubMed ID: 29126833
[TBL] [Abstract][Full Text] [Related]
29. Expression of oxidized protein tyrosine phosphatase and γH2AX predicts poor survival of gastric carcinoma patients.
Hussein UK; Park HS; Bae JS; Kim KM; Chong YJ; Kim CY; Kwon KS; Chung MJ; Lee H; Kang MJ; Moon WS; Jang KY
BMC Cancer; 2018 Aug; 18(1):836. PubMed ID: 30126387
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Kriege M; Jager A; Hooning MJ; Huijskens E; Blom J; van Deurzen CH; Bontenbal M; Collee JM; Menke-Pluijmers MB; Martens JW; Seynaeve C
Cancer; 2012 Feb; 118(4):899-907. PubMed ID: 21761396
[TBL] [Abstract][Full Text] [Related]
32. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
33. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
[TBL] [Abstract][Full Text] [Related]
34. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
[TBL] [Abstract][Full Text] [Related]
35. Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Tovey H; Sipos O; Parker JS; Hoadley KA; Quist J; Kernaghan S; Kilburn L; Salgado R; Loi S; Kennedy RD; Roxanis I; Gazinska P; Pinder SE; Bliss J; Perou CM; Haider S; Grigoriadis A; Tutt A; Cheang MCU
Clin Cancer Res; 2023 Sep; 29(18):3691-3705. PubMed ID: 37574209
[TBL] [Abstract][Full Text] [Related]
36. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI
Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893
[TBL] [Abstract][Full Text] [Related]
37. The HSF1-PARP13-PARP1 complex facilitates DNA repair and promotes mammary tumorigenesis.
Fujimoto M; Takii R; Takaki E; Katiyar A; Nakato R; Shirahige K; Nakai A
Nat Commun; 2017 Nov; 8(1):1638. PubMed ID: 29158484
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
39. Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma.
Na TY; Ka NL; Rhee H; Kyeong D; Kim MH; Seong JK; Park YN; Lee MO
Oncogene; 2016 Oct; 35(41):5435-5445. PubMed ID: 27041572
[TBL] [Abstract][Full Text] [Related]
40. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]